

September 11, 2017

To: British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission

Dear Sirs / Mesdames:

Re: InMed Pharmaceuticals Inc.

We refer to the short form base shelf prospectus of InMed Pharmaceuticals Inc. (the "Company") dated September 11, 2017 relating to offer for sale and issue from time to time of up to \$15,000,000, in the aggregate, of securities of the Company.

We consent to being named and to the use, through incorporation by reference in the above-mentioned short form prospectus, of our report dated October 7, 2016 to the shareholders of the Company on the following financial statements:

Consolidated statements of financial position as at June 30, 2016 and 2015;

Consolidated statements of comprehensive loss, changes in equity and cash flows for the years ended June 30, 2016 and 2015; and

notes, comprising a summary of significant accounting policies and other explanatory information.

We report that we have read the short form base shelf prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,

(signed) "Anton, Bryson & Schindler"

Chartered Professional Accountants LLP